All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Viral hepatitis is ranked as the 7^th^ leading cause of mortality worldwide \[[@pone.0187177.ref001]\], with nearly half of this mortality attributed to hepatitis C virus (HCV) \[[@pone.0187177.ref001]\]. Despite its global burden, the Middle East and North Africa (MENA) remains the most affected region \[[@pone.0187177.ref002], [@pone.0187177.ref003]\]. With the advent of direct-acting antivirals (DAAs) to treat and cure HCV infection \[[@pone.0187177.ref004]\], a global target was set to eliminate HCV infection by 2030 \[[@pone.0187177.ref005], [@pone.0187177.ref006]\].

A key feature of HCV natural history is that not all infected persons develop chronic infection \[[@pone.0187177.ref007]--[@pone.0187177.ref009]\]. While infected persons pass through a stage of acute infection for few months, and develop antibodies against HCV infection, a proportion of them spontaneously clear the infection and becomes HCV antibody (Ab) positive but HCV ribonucleic acid (RNA) negative \[[@pone.0187177.ref007]--[@pone.0187177.ref009]\]. The remainder of infected persons become chronic carriers of the infection and persist as HCV Ab positive and RNA positive \[[@pone.0187177.ref007]--[@pone.0187177.ref009]\]. For a given population, the proportion of chronically infected individuals (HCV Ab positive and RNA positive), out of all ever infected individuals (HCV Ab positive regardless of RNA status), defines the *HCV viremic rate* for this population \[[@pone.0187177.ref010]\].

Assessing and understanding the HCV viremic rate is critical for biological, epidemiological, and public health consequences. The HCV viremic rate provides a measure of HCV spontaneous clearance rate and its determinants, and how this rate may vary by population \[[@pone.0187177.ref011]\]. The HCV viremic rate furnishes also a direct measure of the likelihood that a member of a specific population is chronically infected, as well as an indirect measure of the risk of HCV reinfection in this population \[[@pone.0187177.ref011]\]. It is further essential for estimations of the number of HCV chronic carriers in different populations and countries, and consequences for resource allocation and development of screening and treatment programs. The HCV viremic rate will also play an increasingly important role in assessing and monitoring the progress in (and coverage of) HCV treatment programs in different populations, as we forge ahead towards HCV elimination by 2030.

The HCV viremic rate has been assessed through numerous studies in different populations globally, but its measures show extensive variability across studies \[[@pone.0187177.ref012]--[@pone.0187177.ref021]\]. The HCV clearance rate, which is strongly linked to HCV viremic rate \[[@pone.0187177.ref011]\], has been also assessed in multiple prospective cohort studies \[[@pone.0187177.ref007], [@pone.0187177.ref022]--[@pone.0187177.ref024]\], but its measures also show wide variation across studies \[[@pone.0187177.ref011]\]. To our knowledge, no study have yet been conducted to provide an overall pooled estimate and subgroup pooled estimates for the HCV viremic rate that factor the wide diversity of studies for this measure. No study has also investigated the sources of heterogeneity in available HCV viremic rate measures.

Against this background, we aimed in the present study to provide pooled estimates for the HCV viremic rate, overall and for different risk populations and different countries of the MENA region. We also aimed to investigate the sources of heterogeneity in available measures in MENA. These quantitative assessments were based on a comprehensive and standardized database of systematically gathered HCV viremic rate data.

This study was conducted as part of the MENA HCV Epidemiology Synthesis Project, an ongoing effort to characterize HCV epidemiology and inform public health research, resource allocation, policy, and programing priorities in MENA \[[@pone.0187177.ref011]--[@pone.0187177.ref021], [@pone.0187177.ref025], [@pone.0187177.ref026]\].

Methodology {#sec006}
===========

Data sources {#sec007}
------------

We retrieved studies reporting HCV RNA prevalence measures *strictly* among HCV Ab positive individuals from the MENA HCV Epidemiology Synthesis Project databases. These databases consist of 2,543 studies reporting HCV Ab prevalence among 52,598,736 participants, 47 studies reporting HCV Ab incidence among 29,600 participants, and 338 studies reporting HCV genotypes among 82,257 participants. The retrieved HCV RNA prevalence measures were nearly always extracted from studies whose main outcome measure was HCV Ab prevalence in some specific population. HCV RNA prevalence was a secondary outcome of these studies.

The HCV Synthesis Project databases were compiled through systematic reviews of the literature \[[@pone.0187177.ref012]--[@pone.0187177.ref017], [@pone.0187177.ref019]--[@pone.0187177.ref021]\] that were informed by the Cochrane Collaboration handbook \[[@pone.0187177.ref027]\], and reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@pone.0187177.ref028]\]. The literature searches were conducted using broad search criteria with no language or year restrictions ([S1](#pone.0187177.s003){ref-type="supplementary-material"} and [S2](#pone.0187177.s004){ref-type="supplementary-material"} Boxes), and were based on international databases (PubMed and Embase), regional databases, national databases, and the MENA HIV/AIDS Epidemiology Synthesis Project database \[[@pone.0187177.ref029], [@pone.0187177.ref030]\]. Separate searches were also conducted for the non-indexed literature consisting of public health reports and routine data reporting. The flowcharts summarizing the searches can be found in the previous publications \[[@pone.0187177.ref012]--[@pone.0187177.ref017], [@pone.0187177.ref019]--[@pone.0187177.ref021]\]. The PRISMA checklist for the present study can be found in [S1 Fig](#pone.0187177.s001){ref-type="supplementary-material"}.

The definition of MENA for this project consisted of 24 countries including: Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates (UAE), and Yemen.

Study selection and classification {#sec008}
----------------------------------

All studies reporting a measure of HCV viremic rate were included, provided the sample size was ≥10. The HCV viremic rate was defined as the proportion of HCV Ab positive and RNA positive individuals out of all ever infected (i.e. HCV Ab positive) individuals in the sample. The overall sample size was replaced by stratified measures whenever this was possible while maintaining a subsample size ≥10. The viremic rate measures were classified based on the perceived risk of HCV exposure, as informed by existing classifications \[[@pone.0187177.ref002], [@pone.0187177.ref012]--[@pone.0187177.ref017], [@pone.0187177.ref019]--[@pone.0187177.ref021]\], as follows:

1.  General populations: populations at a low risk of being exposed to HCV infection such as blood donors, healthy adults, healthy children, and pregnant women, among others. Those referred to in included studies as "general populations" were labeled as *other general populations* to avoid confusion with the name of this category.

2.  Populations at intermediate risk: populations at an intermediate risk of being exposed to HCV infection such as health care workers, diabetics, and prisoners, among others).

3.  Populations at high risk of healthcare-related exposures: populations at a high risk of being exposed to HCV infection due to a medical condition that requires frequent injections or blood transfusions such as hemodialysis, thalassemia, and hemophilia patients, among others.

4.  People who inject drugs (PWID) who are at a high risk of being exposed to HCV infection due to sharing of needles or syringes.

5.  Populations with liver-related conditions: populations suffering from liver-related medical conditions that could be linked (or attributed) to HCV infection, such as viral hepatitis, hepatocellular carcinoma, and liver cirrhosis patients, among others.

6.  Special clinical populations: populations with an undetermined risk of HCV exposure such as patients with malignancies, rheumatology disorders, and autoimmune diseases, among others.

Quantitative analysis {#sec009}
---------------------

### Meta-analyses {#sec010}

We conducted meta-analyses to estimate the pooled mean HCV viremic rate for the different risk populations. The methods were adapted from earlier meta-analyses \[[@pone.0187177.ref012]--[@pone.0187177.ref021], [@pone.0187177.ref026]\]. We used DerSimonian-Laird random-effects models with inverse variance weighting whenever we had ≥3 measures to be pooled \[[@pone.0187177.ref031]\]. The Freeman-Tukey type arcsine square-root transformation was used to stabilize the variance of the proportion measures \[[@pone.0187177.ref032]\]. Heterogeneity in effect size between studies was assessed using the Cochran's Q test; a p-value \<0.1 was considered significant \[[@pone.0187177.ref033], [@pone.0187177.ref034]\]. The I^2^ was used to assess the between-study variation associated with differences in effect size \[[@pone.0187177.ref033]\]. The prediction interval was calculated to identify the range where the true effect around the mean falls \[[@pone.0187177.ref033], [@pone.0187177.ref035]\].

Since we did not have sufficient number of studies to do a separate meta-analysis for each individual MENA country, we conducted meta-analyses by country or relevant subregional grouping (Afghanistan and Pakistan, Egypt, Fertile Crescent, Gulf, Iran, and Maghreb). The Fertile Crescent included Iraq, Jordan, Lebanon, Palestine, and Syria. The Gulf included Kuwait, Oman, and Saudi Arabia. The Maghreb included Algeria, Libya, Morocco, and Tunisia. This country/subregion classification included all MENA countries for which data on HCV viremic rate were available.

We further conducted meta-analyses for specific subpopulations among the general population (blood donors, children, pregnant women/antenatal care attendees, and other general populations), and specific subpopulations among the populations at high risk of healthcare-related exposures (hemophilia patients, hemodialysis patients, and thalassemia patients). We also conducted meta-analyses by sex (women only, men only, and mixed-sex), and by sampling method of the original study (convenience sampling, national population-based and probability-based sampling, and other probability-based sampling).

The meta-analyses were conducted using R studio version 3.3.2 \[[@pone.0187177.ref036]\] using the package meta \[[@pone.0187177.ref037]\].

### Meta-regressions and sources of heterogeneity {#sec011}

We conducted univariable and multivariable random-effects meta-regressions to identify the predictors of higher HCV viremic rate and sources of between-study heterogeneity. The following independent variables were specified *a priori* because of epidemiological relevance: risk population, country or subregion, sex, age, HCV Ab prevalence of the sampled population, year of data collection, sample size, and sampling method. Variables with a p-value \<0.1 in the univariable analyses were eligible for inclusion in the final multivariable model. Variables with a p-value \<0.05 in the univariable models or the final multivariable model were considered statistically significant.

Risk population, country/subregion, and sex variables were categorized as described in the above sections. Age was categorized as children and adults. HCV Ab prevalence variable was coded as a categorical variable with four prevalence ranges: 1--10%, 10--30%, 30--50%, and \>50%. The year of data collection variable was coded as a categorical variable with two date ranges: before 2000 and 2000 and thereafter. The sample size variable was categorized as ≥50 and \<50. The sampling method variable was categorized as probability-based sampling and non-probability-based sampling.

For the year of data collection variable, we imputed the missing observations using the median of the results of the subtraction of the year of data collection from the year of publication. A sensitivity analysis using the imputed and the non-imputed observations revealed no impact on the statistical significance of the variable.

The meta-regressions were conducted using Stata/SE version 13 \[[@pone.0187177.ref038]\] using the package metareg \[[@pone.0187177.ref039]\].

Results {#sec012}
=======

Scope of evidence {#sec013}
-----------------

We identified 178 measures for HCV viremic rate among 19,593 HCV Ab positive individuals ([Table 1](#pone.0187177.t001){ref-type="table"}). These measures included 81 in general populations, 20 in populations at intermediate risk, 51 in populations at high risk of healthcare-related exposures, five in PWID, eight in populations with liver-related conditions, and 12 in special clinical populations. One study was considered as "mixed" since the sample included a mix of general populations and an intermediate risk population \[[@pone.0187177.ref040]\].

10.1371/journal.pone.0187177.t001

###### Studies reporting hepatitis C virus (HCV) viremic rate stratified by risk population across countries of the Middle East and North Africa.

![](pone.0187177.t001){#pone.0187177.t001g}

  Country                                                                 First author, year of publication                Years of data collection                                    Population description                                            Number of HCV Ab positive individuals tested for RNA   HCV viremic rate (%)
  ----------------------------------------------------------------------- ------------------------------------------------ ----------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------ ----------------------
  **General populations (n = 81)**                                                                                                                                                                                                                                                                              
  **Egypt**                                                               Abdel-Aziz, 2000 \[[@pone.0187177.ref046]\]      1997                                                        Participants in a population-based survey                         973                                                    65.5
  AbdulQawi, 2011 \[[@pone.0187177.ref047]\]                              2003--08                                         Pregnant women/ANC attendees                                105                                                               79.0                                                   
  Agha, 1998 \[[@pone.0187177.ref048]\]                                   1996--97                                         Pregnant women/ANC attendees                                67                                                                26.9                                                   
  Aguilar, 2008 \[[@pone.0187177.ref049]\]                                \-                                               General population                                          40                                                                67.5                                                   
  Aguilar, 2008 \[[@pone.0187177.ref049]\]                                \-                                               General population                                          33                                                                72.0                                                   
  Arafa, 2005 \[[@pone.0187177.ref050]\]                                  2002--03                                         Participants in a population-based survey                   456                                                               59.9                                                   
  Barakat, 2011 \[[@pone.0187177.ref051]\]                                2005                                             Children                                                    29                                                                75.9                                                   
  Cowgill, 2004 \[[@pone.0187177.ref052]\]                                1999--03                                         General population                                          80                                                                65.0                                                   
  Darwish, 1995 \[[@pone.0187177.ref053]\]                                \-                                               Participants in a population-based survey                   25                                                                76.0                                                   
  Derbala, 2014 \[[@pone.0187177.ref054]\]                                2008--10                                         General population                                          315                                                               100                                                    
  El-Kamary, 2015 \[[@pone.0187177.ref055]\]                              2012--13                                         Pregnant women/ANC attendees                                52                                                                58.0                                                   
  El-Karaksy, 2010 \[[@pone.0187177.ref056]\]                             2006--07                                         Children                                                    15                                                                33.3                                                   
  El-Sadawy, 2004 \[[@pone.0187177.ref057]\]                              \-                                               Participants in a population-based survey                   367                                                               29.7                                                   
  El-Sherbini, 2003 \[[@pone.0187177.ref058]\]                            1994                                             Children                                                    17                                                                41.0                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             15--19 years age group females in a national-based survey   178                                                               67.8                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             20--24 years age group females in a national-based survey   153                                                               66.9                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             25--29 years age group females in a national-based survey   94                                                                62.9                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             30--34 years age group females in a national-based survey   134                                                               70.2                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             35--39 years age group females in a national-based survey   129                                                               69.3                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             40--44 years age group females in a national-based survey   122                                                               65.2                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             45--49 years age group females in a national-based survey   109                                                               60.0                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             50--54 years age group females in a national-based survey   85                                                                70.4                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             55--59 years age group females in a national-based survey   107                                                               68.8                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             10--14 years age group males in a national-based survey     68                                                                76.7                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             20--24 years age group males in a national-based survey     65                                                                62.6                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             25--29 years age group males in a national-based survey     62                                                                73.8                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             30--34 years age group males in a national-based survey     59                                                                53.6                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             35--39 years age group males in a national-based survey     54                                                                66.2                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             40--44 years age group males in a national-based survey     50                                                                61.1                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             45--49 years age group males in a national-based survey     42                                                                65.0                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             50--54 years age group males in a national-based survey     32                                                                74.6                                                   
  El-Zanaty, 2008 \[[@pone.0187177.ref041]\]                              2008                                             55--59 years age group males in a national-based survey     28                                                                71.1                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             1--14 years age group females in a national-based survey    183                                                               75.0                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             15--19 years age group females in a national-based survey   164                                                               66.5                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             20--24 years age group females in a national-based survey   154                                                               66.4                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             25--29 years age group females in a national-based survey   61                                                                81.1                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             30--34 years age group females in a national-based survey   142                                                               63.7                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             35--39 years age group females in a national-based survey   106                                                               69.5                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             40--44 years age group females in a national-based survey   102                                                               69.8                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             45--49 years age group females in a national-based survey   85                                                                75.1                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             50--54 years age group females in a national-based survey   60                                                                73.9                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             55--59 years age group females in a national-based survey   69                                                                73.4                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             1--9 years age group males in a national-based survey       53                                                                69.7                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             10--14 years age group males in a national-based survey     57                                                                57.5                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             15--19 years age group males in a national-based survey     57                                                                78.2                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             20--24 years age group males in a national-based survey     35                                                                68.4                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             25--29 years age group males in a national-based survey     35                                                                66.1                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             30--34 years age group males in a national-based survey     19                                                                72.8                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             35--39 years age group males in a national-based survey     17                                                                42.6                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             40--44 years age group males in a national-based survey     16                                                                78.0                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             45--49 years age group males in a national-based survey     14                                                                70.6                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             50--54 years age group males in a national-based survey     14                                                                67.1                                                   
  MoHP, 2015 \[[@pone.0187177.ref042]\]                                   2015                                             55--59 years age group males in a national-based survey     12                                                                27.5                                                   
  Jhaveri, 2015 \[[@pone.0187177.ref059]\]                                2012--14                                         Pregnant women/ANC attendees                                98                                                                55.0                                                   
  Kalil, 2010 \[[@pone.0187177.ref060]\]                                  2004--05                                         Children                                                    121                                                               72.0                                                   
  Kassem, 2000 \[[@pone.0187177.ref061]\]                                 1996                                             Pregnant women/ANC attendees                                19                                                                73.7                                                   
  Khamis, 2014 \[[@pone.0187177.ref062]\]                                 \-                                               Pregnant women/ANC attendees                                20                                                                45.0                                                   
  Kumar, 1997 \[[@pone.0187177.ref063]\]                                  1994--96                                         Pregnant women/ANC attendees                                65                                                                31.0                                                   
  Nafeh, 2000 \[[@pone.0187177.ref064]\]                                  \-                                               Participants in a population-based survey                   514                                                               63.0                                                   
  Strickland, 2002 \[[@pone.0187177.ref065]\]                             \-                                               Healthy individuals                                         99                                                                74.7                                                   
  Tanaka,2004 \[[@pone.0187177.ref066]\]                                  1999                                             Blood donors                                                317                                                               71.0                                                   
  Zuure,2013 \[[@pone.0187177.ref067]\]                                   2009--10                                         General population                                          11                                                                90.9                                                   
  **Iran**                                                                Doosti, 2009 \[[@pone.0187177.ref068]\]          2003--04                                                    Blood donors                                                      76                                                     62.0
  Farshadpour, 2010 \[[@pone.0187177.ref069]\]                            2007--08                                         Blood donors                                                55                                                                81.8                                                   
  **Iraq**                                                                Obied, 2014 \[[@pone.0187177.ref070]\]           2012--13                                                    Blood donors                                                      20                                                     65.0
  Tawfeeq, 2013 \[[@pone.0187177.ref071]\]                                2011--12                                         Blood donors                                                45                                                                68.9                                                   
  **Jordan**                                                              Rashdan, 2008 \[[@pone.0187177.ref072]\]         2004--06                                                    Blood donors                                                      29                                                     89.6
  **Morocco**                                                             Baha, 2013 \[[@pone.0187177.ref073]\]            2005--11                                                    General population                                                195                                                    70.9
  Benouda, 2009 \[[@pone.0187177.ref074]\]                                2005--07                                         General population                                          158                                                               39.2                                                   
  **Pakistan**                                                            Aziz, 2011 \[[@pone.0187177.ref075]\]            2005--09                                                    Pregnant women/ANC attendees                                      640                                                    79.7
  Donchuk, 2016 \[[@pone.0187177.ref076]\]                                2015--16                                         Outpatient hospital attendees                               1,107                                                             89.0                                                   
  Idrees, 2008 \[[@pone.0187177.ref077]\]                                 1999--07                                         General population                                          857                                                               49.2                                                   
  Idrees, 2008 \[[@pone.0187177.ref077]\]                                 1999--07                                         General population                                          141                                                               50.4                                                   
  Karim, 2016 \[[@pone.0187177.ref078]\]                                  2015                                             Blood donors                                                60                                                                93.0                                                   
  Khokhar, 2004 \[[@pone.0187177.ref079]\]                                2001--02                                         Pregnant women/ANC attendees                                18                                                                72.0                                                   
  Rauf, 2011 \[[@pone.0187177.ref080]\]                                   2009                                             Refugees                                                    18                                                                44.4                                                   
  Rauf, 2011 \[[@pone.0187177.ref080]\]                                   2009                                             Refugees                                                    34                                                                50.0                                                   
  **Palestine**                                                           Shemer-Avni, 1998 \[[@pone.0187177.ref081]\]     \-                                                          Blood donors                                                      34                                                     71.0
  Shemer-Avni, 1998 \[[@pone.0187177.ref081]\]                            \-                                               Outpatient hospital attendees                               11                                                                64.0                                                   
  **Tunisia**                                                             Mejri, 2005 \[[@pone.0187177.ref082]\]           1996                                                        General population                                                72                                                     82.0
  Mejri, 2005 \[[@pone.0187177.ref082]\]                                  1996                                             General population                                          14                                                                71.4                                                   
  **Populations at intermediate risk (n = 20)**                                                                                                                                                                                                                                                                 
  **Algeria**                                                             Mouffok, 2013 \[[@pone.0187177.ref083]\]         2003--12                                                    HIV infected patients                                             22                                                     54.5
  **Egypt**                                                               Abdelwahab, 2012 \[[@pone.0187177.ref084]\]      2008--10                                                    Diabetic patients                                                 140                                                    72.1
  Chehadeh, 2011 \[[@pone.0187177.ref085]\]                               \-                                               Diabetic patients                                           20                                                                80.0                                                   
  Farghaly, 2014 \[[@pone.0187177.ref086]\]                               \-                                               Spouses of index patients                                   18                                                                40.0                                                   
  El-Karaksy, 2010 \[[@pone.0187177.ref056]\]                             2006--07                                         Health care workers                                         25                                                                66.7                                                   
  Hassane, 1998 \[[@pone.0187177.ref087]\]                                \-                                               Household contacts of index patients                        24                                                                50.0                                                   
  Hassane, 1998\[[@pone.0187177.ref087]\]                                 \-                                               Household contacts of index patients                        21                                                                59.1                                                   
  Hassane, 1998\[[@pone.0187177.ref087]\]                                 \-                                               Household contacts of index patients                        11                                                                9.1                                                    
  Madwar, 1999 \[[@pone.0187177.ref088]\]                                 \-                                               Prisoners                                                   28                                                                100                                                    
  Munier, 2013 \[[@pone.0187177.ref089]\]                                 2008--10                                         Diabetic patients                                           43                                                                77.2                                                   
  Mohamed, 2013 \[[@pone.0187177.ref090]\]                                \-                                               Health care workers                                         79                                                                51.2                                                   
  Shalaby, 2010 \[[@pone.0187177.ref091]\]                                2007                                             Barbers and barbers' clients                                77                                                                73.0                                                   
  **Kuwait**                                                              Chehadeh, 2011 \[[@pone.0187177.ref085]\]        \-                                                          Diabetic patients (Kuwaitis)                                      11                                                     72.7
  Chehadeh, 2011 \[[@pone.0187177.ref085]\]                               \-                                               Diabetic patients (Egyptians)                               20                                                                80.0                                                   
  **Lebanon**                                                             Mahfoud, 2010 \[[@pone.0187177.ref092]\]         2007--08                                                    Prisoners                                                         12                                                     50.0
  **Libya**                                                               Elzouki, 2014 \[[@pone.0187177.ref093]\]         2008--09                                                    Health care workers                                               12                                                     33.3
  **Morocco**                                                             Cacoub, 2000 \[[@pone.0187177.ref094]\]          1995--96                                                    Inpatients and outpatients                                        60                                                     75.0
  Rebbani, 2013 \[[@pone.0187177.ref095]\]                                2006--10                                         HIV infected patients                                       27                                                                77.8                                                   
  **Pakistan**                                                            Qureshi, 2007 \[[@pone.0187177.ref096]\]         \-                                                          Health care workers                                               21                                                     76.0
  Zuberi, 2009 \[[@pone.0187177.ref097]\]                                 2004--08                                         Inpatients                                                  10                                                                90.0                                                   
  **Populations at high risk of healthcare-related exposures (n = 51)**                                                                                                                                                                                                                                         
  **Egypt**                                                               Abdelwahab, 2012 \[[@pone.0187177.ref098]\]      \-                                                          Hemophilia patients                                               40                                                     47.5
  Hussein, 2014 \[[@pone.0187177.ref099]\]                                2007--08                                         Thalassemia patients                                        48                                                                100                                                    
  Omar, 2011 \[[@pone.0187177.ref100]\]                                   \-                                               Thalassemia patients                                        75                                                                74.3                                                   
  Said, 2013 \[[@pone.0187177.ref101]\]                                   \-                                               Thalassemia patients                                        47                                                                100                                                    
  Salama, 2015 \[[@pone.0187177.ref102]\]                                 \-                                               Thalassemia patients                                        40                                                                55.0                                                   
  **Iran**                                                                Abdollahi, 2008 \[[@pone.0187177.ref103]\]       2003                                                        Hemophilia patients                                               145                                                    80.2
  Alvai, 2005 \[[@pone.0187177.ref104]\]                                  2002                                             Thalassemia patients                                        13                                                                84.6                                                   
  Asguar, 2007 \[[@pone.0187177.ref105]\]                                 \-                                               Hemophilia patients                                         21                                                                80.9                                                   
  Assarehzadegan, 2012 \[[@pone.0187177.ref106]\]                         2008--09                                         Hemophilia patients                                         47                                                                89.4                                                   
  Azarkeivan, 2011 \[[@pone.0187177.ref107]\]                             2008                                             Thalassemia patients                                        170                                                               66.0                                                   
  Broumand, 2002 \[[@pone.0187177.ref108]\]                               \-                                               Hemodialysis patients                                       105                                                               48.6                                                   
  Faranoush, 2006 \[[@pone.0187177.ref109]\]                              \-                                               Thalassemia patients                                        222                                                               60.0                                                   
  Ghane, 2012 \[[@pone.0187177.ref110]\]                                  2010                                             Thalassemia patients                                        36                                                                77.8                                                   
  Joukar, 2011 \[[@pone.0187177.ref111]\]                                 2009                                             Hemodialysis patients                                       61                                                                50.8                                                   
  Kalantari, 2011 \[[@pone.0187177.ref112]\]                              2009                                             Thalassemia patients                                        50                                                                62.0                                                   
  Kalantari, 2011 \[[@pone.0187177.ref112]\]                              2009                                             Hemophilia patients                                         495                                                               70.1                                                   
  Makhlough, 2008 \[[@pone.0187177.ref113]\]                              2006                                             Hemodialysis patients                                       39                                                                53.8                                                   
  Mousavi, 2002 \[[@pone.0187177.ref114]\]                                \-                                               Thalassemia patients                                        22                                                                77.3                                                   
  Samimi-Rad, 2007 \[[@pone.0187177.ref115]\]                             2004                                             Bleeding disorder patients                                  34                                                                68.0                                                   
  Samimi-Rad, 2008 \[[@pone.0187177.ref116]\]                             2005                                             Hemodialysis patients                                       14                                                                64.3                                                   
  Ziaee, 2005 \[[@pone.0187177.ref117]\]                                  2000                                             Thalassemia patients                                        44                                                                56.8                                                   
  **Iraq**                                                                Al-Kubaisy, 2006 \[[@pone.0187177.ref118]\]      1998                                                        Hemodialysis patients                                             50                                                     76.0
  Al-Kubaisy, 2006 \[[@pone.0187177.ref118]\]                             1998                                             Thalassemia patients                                        20                                                                70.0                                                   
  Abdullah, 2012 \[[@pone.0187177.ref119]\]                               2010                                             Hemophiliacs co-infected with HIV                           92                                                                26.1                                                   
  Khaled, 2014 \[[@pone.0187177.ref120]\]                                 2012                                             Thalassemia patients                                        50                                                                88.0                                                   
  Shihab, 2014 \[[@pone.0187177.ref121]\]                                 2012--13                                         Hemodialysis patients                                       52                                                                61.5                                                   
  **Jordan**                                                              Al-Sweedan, 2011 \[[@pone.0187177.ref122]\]      2008                                                        Thalassemia patients                                              40                                                     50.0
  Bdour, 2002 \[[@pone.0187177.ref123]\]                                  \-                                               Hemodialysis patients                                       92                                                                31.5                                                   
  **Lebanon**                                                             Abdelnour, 1997 \[[@pone.0187177.ref124]\]       \-                                                          Thalassemia patients                                              17                                                     65.0
  Ramia, 2002 \[[@pone.0187177.ref125]\]                                  1999--00                                         Hemodialysis patients                                       55                                                                34.5                                                   
  **Libya**                                                               Elzouki, 1995 \[[@pone.0187177.ref126]\]         \-                                                          Hemodialysis patients                                             32                                                     72.0
  **Morocco**                                                             Benani, 1997 \[[@pone.0187177.ref127]\]          \-                                                          Hemodialysis patients                                             49                                                     48.9
  Doblali, 2014 \[[@pone.0187177.ref128]\]                                2010--12                                         Hemodialysis patients                                       26                                                                65.4                                                   
  Foullous, 2015 \[[@pone.0187177.ref129]\]                               \-                                               Hemodialysis patients                                       194                                                               54.1                                                   
  Lioussfi, 2014 \[[@pone.0187177.ref130]\]                               2009                                             Hemodialysis patients                                       43                                                                69.8                                                   
  **Oman**                                                                Al Naamani, 2015 \[[@pone.0187177.ref131]\]      1991--01                                                    Thalassemia patients                                              65                                                     51.0
  **Palestine**                                                           El-Ottol, 2010 \[[@pone.0187177.ref132]\]        2007                                                        Hemodialysis patients                                             44                                                     84.1
  **Saudi Arabia**                                                        Hussein, 1994 \[[@pone.0187177.ref133]\]         1993                                                        Hemodialysis patients                                             27                                                     70.4
  **Syria**                                                               Abdulkarim, 1998 \[[@pone.0187177.ref134]\]      \-                                                          Multi-transfused patients                                         56                                                     87.5
  Yazaji, 2016 \[[@pone.0187177.ref135]\]                                 2012--13                                         Hemodialysis patients                                       18                                                                22.2                                                   
  **Tunisia**                                                             Ayed, 2003 \[[@pone.0187177.ref136]\]            2001                                                        Hemodialysis patients                                             310                                                    75.5
  Ayed, 2003 \[[@pone.0187177.ref136]\]                                   2001                                             Hemodialysis patients                                       55                                                                70.9                                                   
  Ayed, 2003 \[[@pone.0187177.ref136]\]                                   2001                                             Hemodialysis patients                                       44                                                                90.9                                                   
  Ayed, 2003 \[[@pone.0187177.ref136]\]                                   2001                                             Hemodialysis patients                                       60                                                                93.3                                                   
  Ayed, 2003 \[[@pone.0187177.ref136]\]                                   2001                                             Hemodialysis patients                                       243                                                               60.5                                                   
  Ayed, 2003 \[[@pone.0187177.ref136]\]                                   2001                                             Hemodialysis patients                                       116                                                               71.5                                                   
  Ben Othman, 2004 \[[@pone.0187177.ref137]\]                             2000--02                                         Hemodialysis patients                                       42                                                                76.2                                                   
  Ben Othman, 2004 \[[@pone.0187177.ref137]\]                             2000--02                                         Hemodialysis patients                                       15                                                                86.7                                                   
  Ben Othman, 2004 \[[@pone.0187177.ref137]\]                             2000--02                                         Hemodialysis patients                                       33                                                                78.8                                                   
  Hmaied, 2006 \[[@pone.0187177.ref138]\]                                 2001--03                                         Hemodialysis patients                                       79                                                                73.0                                                   
  Sassi, 2000 \[[@pone.0187177.ref139]\]                                  \-                                               Hemodialysis patients                                       27                                                                51.8                                                   
  **People who inject drugs (n = 5)**                                                                                                                                                                                                                                                                           
  **Afghanistan**                                                         Nasir, 2011 \[[@pone.0187177.ref140]\]           2006--08                                                    People who inject drugs                                           165                                                    58.2
  Nasir, 2011 \[[@pone.0187177.ref140]\]                                  2006--08                                         People who inject drugs                                     12                                                                41.7                                                   
  Nasir, 2011 \[[@pone.0187177.ref140]\]                                  2006--08                                         People who inject drugs                                     44                                                                59.1                                                   
  **Iran**                                                                Mansoori, 2003 \[[@pone.0187177.ref141]\]        1998--00                                                    HIV patients with intravenous drug use as main mode of exposure   15                                                     80.0
  **Lebanon**                                                             Mahfoud, 2010 \[[@pone.0187177.ref142]\]         2007--08                                                    People who inject drugs                                           56                                                     50.0
  **Populations with liver-related conditions (n = 4)**                                                                                                                                                                                                                                                         
  **Algeria**                                                             Bensalem, 2016 \[[@pone.0187177.ref143]\]        2012                                                        Patients referred to a confirmatory laboratory test               3,204                                                  66.2
  **Algeria, Morocco, Tunisia**                                           Bahri, 2011 \[[@pone.0187177.ref144]\]           2002--05                                                    Hepatocellular carcinoma patients                                 98                                                     93.0
  **Egypt**                                                               Angelico, 1997 \[[@pone.0187177.ref145]\]        1993--95                                                    Chronic liver disease patients                                    91                                                     55.0
  Quinti, 1997 \[[@pone.0187177.ref146]\]                                 \-                                               Acute viral hepatitis patients                              23                                                                87.0                                                   
  Strickland, 2002 \[[@pone.0187177.ref065]\]                             \-                                               Chronic liver disease patients                              138                                                               69.6                                                   
  **Iraq**                                                                Al-Kubaisy, 2014 \[[@pone.0187177.ref147]\]      2000--03                                                    Hepatocellular carcinoma patients                                 17                                                     70.8
  **Morocco**                                                             Tayeb, 2012 \[[@pone.0187177.ref148]\]           \-                                                          HCV Ab positive patients                                          46                                                     43.5
  **Pakistan**                                                            Sundus, 2013 \[[@pone.0187177.ref149]\]          2009--10                                                    Hepatitis patients                                                151                                                    98.0
  **Special clinical populations (n = 16)**                                                                                                                                                                                                                                                                     
  **Egypt**                                                               Cowgill, 2004 \[[@pone.0187177.ref052]\]         1999--03                                                    Non-Hodgkin\'s lymphoma patients                                  106                                                    89.0
  El Garf, 2012 \[[@pone.0187177.ref150]\]                                2009                                             Rheumatoid arthritis patients                               21                                                                71.4                                                   
  Mahmoud, 2011 \[[@pone.0187177.ref151]\]                                2009--10                                         Rheumatoid arthritis patients                               22                                                                63.6                                                   
  Mostafa, 2003 \[[@pone.0187177.ref152]\]                                2000--01                                         Cancer patients on chemotherapy                             13                                                                38.5                                                   
  Mostafa, 2003 \[[@pone.0187177.ref152]\]                                2000--01                                         Cancer patients on chemotherapy                             44                                                                47.7                                                   
  Sabry, 2005 \[[@pone.0187177.ref153]\]                                  \-                                               Glomerulonephritis patients                                 90                                                                55.6                                                   
  Sharaf-Eldeen, 2007 \[[@pone.0187177.ref154]\]                          \-                                               Lichen planus patients                                      43                                                                76.8                                                   
  Youssef, 2009 \[[@pone.0187177.ref155]\]                                \-                                               Patients with liver complaints                              156                                                               57.7                                                   
  **Pakistan**                                                            Mahboob, 2003 \[[@pone.0187177.ref156]\]         1999--01                                                    Lichen planus patients                                            16                                                     62.5
  **Saudi Arabia**                                                        Halawani, 2012 \[[@pone.0187177.ref157]\]        2007--09                                                    Urticarial patients                                               12                                                     75.0
  Halawani, 2010 \[[@pone.0187177.ref158]\]                               \-                                               Lichen planus patients                                      24                                                                62.5                                                   
  **Tunisia**                                                             Lakhoua Gorgi, 2010 \[[@pone.0187177.ref159]\]   1987--04                                                    Renal transplant patients                                         24                                                     91.7
  **Mixed populations (n = 1)**                                                                                                                                                                                                                                                                                 
  **Libya**                                                               Saleh, 1994 \[[@pone.0187177.ref040]\]           1992                                                        Blood donors, health care workers, and outpatients                18                                                     66.7

Abbreviations: Ab = Antibody, ANC = Antenatal care, HCV = Hepatitis C virus, MoHP = Ministry of Health and Population, RNA = Ribonucleic acid.

There were data on HCV viremic rate in 16 out of the 24 MENA countries ([Table 1](#pone.0187177.t001){ref-type="table"}). Egypt contributed the largest number of data points (n = 89), and the majority of these were from studies in general populations.

HCV viremic rate {#sec014}
----------------

HCV viremic rate varied across and within the risk populations with a broad range of 9--100% and a median of 68.8% ([Table 2](#pone.0187177.t002){ref-type="table"}). The overall pooled mean HCV viremic rate (across all data points) was 67.6% (95% confidence interval (CI): 64.9--70.3%).

10.1371/journal.pone.0187177.t002

###### Pooled mean estimate for hepatitis C virus (HCV) viremic rate by risk population in the Middle East and North Africa.

![](pone.0187177.t002){#pone.0187177.t002g}

  Population at risk                                      Studies   HCV Ab prevalence[^a^](#t002fn001){ref-type="table-fn"}   HCV RNA positivity among HCV Ab positive individuals                                                                                            
  ------------------------------------------------------- --------- --------------------------------------------------------- ------------------------------------------------------ ------------ ----------------------- --------------------------- ----------------------- ----------------
  General populations                                     81        10.4 (8.4--12.5)                                          10,448                                                 26--100      66.9 (62.6--71.1)       1,510.9 (p \< 0.0001)       94.7 (93.9--95.3)       29.1--95.3
  Populations at intermediate risk                        20        10.4 (6.8--14.6)                                          682                                                    9--100       67.1 (58.6--75.2)       85.2 (p \< 0.0001)          77.7 (66.0--85.4)       30.9--94.9
  Populations at high risk healthcare-related exposures   51        31.3 (36.0--36.7)                                         3,814                                                  22--100      68.5 (63.5--73.3)       478.0 (p \< 0.0001)         89.5 (87.1--91.5)       33.7--94.8
  People who inject drugs                                 5         42.2 (23.9--61.8)                                         292                                                    50--80       57.4 (49.4--65.2)       5.6 (p = 0.23)              28.8 (0.0--72.3)        37.2--76.4
  Populations with liver-related conditions               8         6.5 (43.8--83.0)                                          3,768                                                  43--98       75.5 (61.0--87.6)       190.0 (p \< 0.0001)         96.3 (94.5--97.5)       22.3--100
  Special clinical populations                            12        30.1 (19.6--41.8)                                         571                                                    38--91       67.4 (56.7--77.3)       62.6 (p \< 0.0001)          82.4 (70.6--89.5)       28.7--96.2
  All studies[^e^](#t002fn005){ref-type="table-fn"}       **178**   **18.8 (16.7--21.1)**                                     **19,593**                                             **9--100**   **67.6 (64.9--70.3)**   **2,351.7 (p \< 0.0001)**   **92.5 (91.6--93.2)**   **33.7--93.8**

^a^ This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.

^b^ Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size.

^c^ I^2^: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

^d^ Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.

^e^ A study including a mixed population group \[[@pone.0187177.ref040]\] was also considered in the meta-analysis.

Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.

Across the risk populations ([Table 2](#pone.0187177.t002){ref-type="table"}), the pooled mean HCV viremic rate was lowest at 57.4% (95% CI: 49.4--65.2%) in PWID, followed by 66.9% (95% CI: 62.6--71.1%) in the general populations, 67.1% (95% CI: 58.6--75.2%) in the populations at intermediate risk, 67.4% (95% CI: 56.7--77.3%) in the special clinical populations, 68.5% (95% CI: 63.5--73.3%) in the populations at high risk healthcare-related exposures, and 75.5% (95% CI: 61.0--87.6%) in populations with liver-related conditions.

Across countries or subregions ([Table 3](#pone.0187177.t003){ref-type="table"}), the pooled mean HCV viremic rate was lowest at 62.1% (95% CI: 50.0--72.7%) in the Fertile Crescent, followed by 65.9% (95% CI: 55.3--75.9%) in the Gulf, 67.0% (95% CI: 63.1--70.8%) in Egypt, 68.6% (95% CI: 63.2--73.8%) in Iran, 70.4% (95% CI: 57.4--82.0%) in Afghanistan and Pakistan, and 70.4% (95% CI: 65.5--75.1%) in the Maghreb.

10.1371/journal.pone.0187177.t003

###### Pooled mean estimate for hepatitis C virus (HCV) viremic rate by country or relevant subregion in the Middle East and North Africa.
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  Country or relevant subregion   Studies   HCV Ab prevalence[^a^](#t003fn001){ref-type="table-fn"}   HCV RNA positivity among HCV Ab positive individuals                                                                                            
  ------------------------------- --------- --------------------------------------------------------- ------------------------------------------------------ ------------ ----------------------- --------------------------- ----------------------- ----------------
  Afghanistan/Pakistan            15        20 (13.1--27.9)                                           3,294                                                  41--98       70.4 (57.4--82.0)       628.9 (p \< 0.0001)         97.8 (97.2--98.3)       17.1--100
  Egypt                           89        16.9 (14.2--19.9)                                         8,348                                                  9--100       67.0 (63.1--70.8)       1,108.0 (p \< 0.0001)       92.1 (90.8--93.1)       31.5--94.4
  Fertile Crescent                20        18.4 (13.2--24.2)                                         810                                                    22--89       62.1 (50.0--72.7)       182.9 (p \< 0.0001)         89.6 (85.4--92.6)       14.2--98.6
  Gulf                            6         20.5 (7.9--36.9)                                          159                                                    51--80       65.9 (55.3--75.9)       7.9 (p = 0.15)              37.2 (0.0--75.0)        38.9--88.7
  Iran                            19        28.6 (16.1--43.0)                                         1,664                                                  48--89       68.6 (63.2--73.8)       74.3 (p \< 0.0001)          75.8 (62.3--84.4)       46.8--86.9
  Maghreb                         29        18.2 (13.9--22.9)                                         5,318                                                  33--93       70.4 (65.5--75.1)       222.7 (p \< 0.0001)         87.4 (83.1--90.7)       45.0--90.7
  All countries                   **178**   **18.8 (16.7--21.1)**                                     **19,593**                                             **9--100**   **67.6 (64.9--70.3)**   **2,351.7 (p \< 0.0001)**   **92.5 (91.6--93.2)**   **33.7--93.8**

^a^ This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.

^b^ Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size.

^c^ I^2^: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

^d^ Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.

Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.

Among the general populations ([Table 4](#pone.0187177.t004){ref-type="table"}), the pooled mean HCV viremic rate was lowest among children (54.0%, 95% CI: 37.6--70.0%), and highest among blood donors (76.3%, 95% CI: 68.6--84.0%). Among populations at high risk of healthcare-related exposures, the pooled mean HCV viremic rate was lowest among hemodialysis patients (66.5%, 95% CI: 59.9--73.2%), and highest among hemophilia patients (73.6%, 95% CI: 63.9--82.3%)

10.1371/journal.pone.0187177.t004

###### Pooled mean estimate for hepatitis C virus (HCV) viremic rate by risk subpopulation, sex, and sampling method in the Middle East and North Africa.
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  Variables                                                                            Studies   HCV Ab prevalence[^a^](#t004fn001){ref-type="table-fn"}   HCV RNA positivity among HCV Ab positive individuals                                                                             
  ------------------------------------------------------------------------------------ --------- --------------------------------------------------------- ------------------------------------------------------ --------- ------------------- ----------------------- ------------------- ------------
  **Subpopulations among the general population**                                                                                                                                                                                                                                           
  Blood donors                                                                         8         1.4 (0.5--2.7)                                            636                                                    62--93    76.3 (68.6--84.0)   30.94 (p \< 0.0001)     77.4 (55.2--88.6)   46.5--95.6
  Children                                                                             7         3.7 (1.1--7.6)                                            225                                                    27--75    54.0 (37.6--70.0)   26.1 (p \< 0.0002)      77.0 (51.9--89.0)   7.6--96.4
  Pregnant women/ANC attendees                                                         9         7.7 (5.8--9.9)                                            1,084                                                  26--79    58.1 (42.1--73.4)   149.3 (p \< 0.0001)     94.6 (91.8--96.5)   7.4--99.2
  Other general populations                                                            57        13.9 (10.8--17.1)                                         8503                                                   29--100   68.1 (62.9--73.1)   1,290.8 (p \< 0.0001)   95.7 (94.9--96.3)   28.8--96.6
  **Subpopulations among the populations at high risk healthcare-related exposures**                                                                                                                                                                                                        
  Hemophilia patients                                                                  6         55.7 (35.6--74.9)                                         782                                                    48--89    73.6 (63.9--82.3)   25.7 (p \< 0.0001)      80.5 (58.0--91.0)   40.0--96.6
  Hemodialysis patients                                                                27        26.3 (22.0--30.1)                                         1,967                                                  26--93    66.5 (59.5--73.2)   241.6 (p \< 0.0001)     89.2 (85.6--92.0)   30.4--94.4
  Thalassemia patients                                                                 16        29.6 (22.2--37.5)                                         1,027                                                  34--100   72.1 (61.6--81.6)   177.5 (p \< 0.0001)     91.5 (87.9--94.1)   26.3--99.9
  **Sex**                                                                                                                                                                                                                                                                                   
  Females                                                                              33        11.0 (8.4--13.9)                                          2,712                                                  26--100   65.4 (60.1--70.6)   225.5 (p \< 0.0001)     85.8 (81.1--89.4)   36.3--89.6
  Males                                                                                26        15.1 (10.4--20.5)                                         2,953                                                  27--100   67.4 (58.1--76.0)   582.5 (p \< 0.0001)     95.7 (94.6--96.6)   20.0--99.4
  Mixed                                                                                119       22.5 (19.4--25.7)                                         13,928                                                 9--100    68.2 (64.9--71.3)   1,542.1 (p \< 0.0001)   92.3 (91.3--93.2)   34.9--93.9
  **Sampling methods**                                                                                                                                                                                                                                                                      
  Convenience sampling                                                                 126       22.4 (19.4--25.5)                                         13,713                                                 9--100    68.2 (64.8--71.6)   1,843.8 (p \< 0.0001)   93.2 (92.4--94.0)   31.5--95.6
  National population-based and probability-based sampling                             41        11.2 (7.9--14.9)                                          3,112                                                  28--82    68.7 (66.6--70.8)   57.92 (p \< 0.0003)     30.9 (0.0--53.1)    60.7--76.1
  Other probability-based sampling                                                     11        13.9 (5.9--24.5)                                          2,768                                                  29--76    58.7 (49.4--67.6)   170.4 (p \< 0.0001)     94.1 (91.3--96.0)   25.8--87.8

^a^ This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.

^b^ Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size.

^c^ I^2^: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

^d^ Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.

Abbreviations: Ab = Antibody, ANC = Antenatal care, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.

By sex ([Table 4](#pone.0187177.t004){ref-type="table"}), the pooled mean HCV viremic rate was 65.4% (95% CI: 60.1--70.6%) among females, 67.4% (95% CI: 58.1--76.0%) among males, and 68.2% (95% CI: 64.9--71.3%) among the mixed-sex samples.

By sampling method ([Table 4](#pone.0187177.t004){ref-type="table"}), the pooled mean HCV viremic rate was 58.7% (95% CI: 49.4--67.6%) for studies using probability-based sampling but not at the national level, 68.7% (95% CI: 66.6--70.8%) for studies using probability-based sampling at the national level, and 68.2% (95% CI: 64.8--71.6%) in studies using convenience sampling.

There was (overall) evidence for strong heterogeneity in HCV viremic rate in all the different meta-analyses with generally a p-value \<0.0001 (Tables [2](#pone.0187177.t002){ref-type="table"}--[4](#pone.0187177.t004){ref-type="table"}). The I^2^ for the pooled estimates indicated that the vast majority of the variation was due to true variation in HCV viremic rate across studies rather than chance (generally I^2^ \>\>50%). The prediction intervals were generally very broad confirming substantial variation in measured HCV viremic rate across studies. Forest plots for the meta-analyses by risk population can be found in [S2 Fig](#pone.0187177.s002){ref-type="supplementary-material"}.

Predictors of HCV viremic rate and sources of heterogeneity {#sec015}
-----------------------------------------------------------

[Table 5](#pone.0187177.t005){ref-type="table"} displays the results of the univariable meta-regressions to identify the predictors of HCV viremic rate and sources of between-study heterogeneity. None of the hypothesized predictors were statistically significant (p-value \>0.05), and none were eligible for inclusion in the final multivariable model (p-value \>0.1). Therefore, no multivariable meta-regression was conducted.

10.1371/journal.pone.0187177.t005

###### Univariable meta-regression models for hepatitis C virus (HCV) viremic rate in the Middle East and North Africa.
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                                                                                            Number of studies   Univariable analysis   
  -------------------------------------------------------- -------------------------------- ------------------- ---------------------- ----
  **Risk population**                                      General populations              81                  1                      \-
  Populations at intermediate risk                         20                               0.9 (0.6--1.6)      0.887                  
  Populations of high risk healthcare-related exposures    51                               1.1 (0.8--1.5)      0.483                  
  PWID                                                     5                                0.6 (0.3--1.7)      0.375                  
  Populations with liver-related conditions                8                                1.7 (0.8--3.6)      0.147                  
  Special clinical populations                             12                               1.0 (0.5--1.8)      0.97                   
  **Region**                                               Egypt                            89                  1                      \-
  Afghanistan/Pakistan                                     15                               1.2 (0.7--2.1)      0.541                  
  Fertile Crescent[^a^](#t005fn001){ref-type="table-fn"}   20                               0.8 (0.5--1.3)      0.309                  
  Gulf[^b^](#t005fn002){ref-type="table-fn"}               6                                1.0 (0.4--2.3)      0.971                  
  Iran                                                     19                               1.1 (0.6--1.8)      0.793                  
  Maghreb[^c^](#t005fn003){ref-type="table-fn"}            29                               1.1 (0.7--1.7)      0.566                  
  **Sex**                                                  Females                          33                  1                      \-
  Males                                                    26                               1.1 (0.7--1.9)      0.66                   
  Mixed                                                    119                              1.1 (0.7--1.6)      0.559                  
  **Age**                                                  Children                         14                  1                      \-
  Adults                                                   164                              1.5 (0.9--2.6)      0.139                  
  **Prevalence of HCV Ab positive**                        1--10%                           56                  1                      \-
  10--30%                                                  69                               1.2 (0.8--1.7)      0.331                  
  30--50%                                                  32                               1.1 (0.7--1.8)      0.637                  
  \>50%                                                    16                               1.6 (0.9--2.8)      0.113                  
  **Year of data collection**                              Before 2000                      42                  1                      \-
  2000 and thereafter                                      136                              1.2 (0.9--1.7)      0.217                  
  **Sample size**                                          \<50                             89                  1                      \-
  ≥50                                                      89                               1.0 (0.7--1.4)      0.75                   
  **Sampling methods**                                     Non-probability based sampling   126                 1                      \-
  Probability based sampling                               50                               0.8 (0.6--1.2)      0.272                  

^a^ Fertile Crescent includes: Iraq, Jordan, Lebanon, Palestine, and Syria.

^b^ Gulf includes: Kuwait, Oman, and Saudi Arabia.

^c^ Maghreb includes: Algeria, Libya, Morocco, and Tunisia.

Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, PWID = People who inject drugs, OR = Odds ratio.

Though no variables were significantly predictive of HCV viremic rate, there were notably trends of lower viremic rate for females and children ([Table 5](#pone.0187177.t005){ref-type="table"}), and trends of higher viremic rate for populations with liver-related conditions and for populations with high (\>50%) HCV Ab prevalence.

Discussion {#sec016}
==========

Through a comprehensive analysis of systematically extracted data, we investigated HCV viremic rate in the MENA region. We found that about two-thirds of HCV Ab positive individuals are chronically infected with HCV infection. Though the viremic rate varied widely across studies, the pooled mean HCV viremic rate was similar regardless of risk population or subpopulation, country or subregion, HCV Ab prevalence, sex, or study sampling method. The overall pooled mean viremic rate of 67.6% (95% CI: 64.9--70.3%) was also similar to that found in large population-based and nationally-representative surveys such as those of the Demographic and Health Surveys in Egypt that reported a viremic rate of 66.6% (in 2008) \[[@pone.0187177.ref041]\] and 70.2% (in 2015) \[[@pone.0187177.ref042]\].

HCV viremic rate is defined as the proportion of *chronically infected* individuals (HCV Ab positive and RNA positive), out of all *ever infected* individuals (HCV Ab positive regardless of RNA status). Accordingly, it is closely linked to HCV clearance rate, defined as the proportion of people who spontaneously clear their infection---that is the proportion of people who clear their *acute infection* and do not become *chronically infected* \[[@pone.0187177.ref011]\]. Our results then imply that over 30% of infected individuals spontaneously clear their infection, a higher proportion than that estimated in prospective cohort studies of about 25% \[[@pone.0187177.ref007], [@pone.0187177.ref023]\]. While prospective studies provide a direct approach to estimating the clearance rate, there are known methodological limitations and potential biases that may lead to underestimation of clearance rate \[[@pone.0187177.ref007], [@pone.0187177.ref011], [@pone.0187177.ref022]\]. Our results, using an independent methodology from that of prospective studies, suggest that one-third of infected individuals spontaneously clear their infection.

In planning for this study, our implied hypothesis was that we will identify several predictors of higher HCV viremic rate. PWID and populations at high risk of healthcare-related exposures may have a weaker immune system and are at a higher risk of HCV reinfection, therefore should have a higher viremic rate. Female sex is associated with higher spontaneous clearance rate \[[@pone.0187177.ref007], [@pone.0187177.ref023], [@pone.0187177.ref043]\], and therefore we expected the viremic rate among men to be larger than that among women. We further expected a higher viremic rate in populations with higher HCV Ab prevalence, as HCV Ab prevalence can be seen as a proxy for the risk of repeated HCV exposures. Lastly, we expected a higher viremic rate in populations with liver-related conditions, since the presence of these conditions could be indicative of chronic HCV infection.

Nevertheless, none of these hypothesized effects were identified as statistically significant in our meta-regression analyses. Though there was a trend of lower viremic rate in women-only studies, and trends of higher viremic rate in populations with liver-related conditions and populations with higher (\>50%) HCV Ab prevalence, none of these trends reached statistical significance. These results suggest that either some of these effects may not be present as originally hypothesized, or that the effect size of these effects was not large enough to be detected in our sample of 178 viremic rate measures, or that the heterogeneity in the effect size lowered the power of the analysis to detect these differences.

Though we could not identify any significant predictor of HCV viremic rate, the viremic rate varied widely across studies. This may suggest that much of this variation could be due to random effects, such as those related to the complex laboratory methods used in assessing the viremic rate. Assessment of HCV viremic rate requires a two-test algorithm, for HCV Ab and HCV RNA, and the diagnostic assays and protocols can vary from one study to another. Different assays, whether for HCV Ab or for HCV RNA, may also have different sensitivities and specificities, which can impact the estimated HCV viremic rate \[[@pone.0187177.ref044], [@pone.0187177.ref045]\]. Even small random errors in assessing the denominator (HCV Ab positive cases), or the numerator (HCV RNA positive cases), can lead to large variation in calculated viremic rate.

Another source of random errors in calculated HCV viremic rate could be sampling variation as the "effective" sample size in viremic rate studies (the number of HCV Ab positive cases), tend to be small ([Table 1](#pone.0187177.t001){ref-type="table"}). The number of HCV Ab positive cases is most often a *subsample* of the original study sample size---the original study sample size is the number of individuals recruited in the original study whose serostatus could be HCV Ab negative or HCV Ab positive. The median size of the (sub) sample of HCV Ab positive cases in included studies was only 50. With a viremic rate of 67.6% (as was the pooled estimate), this small median sample size leads to a wide confidence interval (95% CI: 53.3%-80.5%). This highlights how (sub) sample size could be a major cause of the observed variation.

The large variations in HCV viremic rate across studies ([Table 1](#pone.0187177.t001){ref-type="table"}), but the small variations in the pooled mean HCV viremic rates (Tables [2](#pone.0187177.t002){ref-type="table"}--[4](#pone.0187177.t004){ref-type="table"}), suggest caution against using the highly variable and possibly error-prone study-specific viremic rates in estimations of the number of HCV chronic carriers in different populations and countries, instead of the stable pooled means. We advocate here for the use of one standardized HCV viremic rate, say the overall pooled mean estimated in this study ([Table 2](#pone.0187177.t002){ref-type="table"}), in ongoing chronic HCV infection estimations---such as the global estimations being conducted for the World Health Organization \[[@pone.0187177.ref003]\]. We further advocate for the use of pooled means, rather than study-specific estimates, for assessing and monitoring the progress in (and coverage of) HCV treatment programs, as we forge ahead towards HCV elimination by 2030. Of notice here that this progress monitoring will require repeated population-based measures of HCV antibody positivity and HCV RNA positivity in the same population, with sufficiently large sample sizes to assess statistically the trends in HCV viremic rate.

Our study has several limitations. The availability of data varied by risk population and country, and we did not identify any HCV viremic rate data for eight MENA countries. The number of studies was limited for some risk populations---only five studies were identified for PWID, and these were mostly conducted among PWID with access to prevention programs. Sample size varied across studies, and the sampled risk population may not have been representative of the wider risk population in the country. Despite these limitations, we identified a substantial volume of viremic rate data in MENA that facilitated the conduct of different types of analyses, thereby generating informative inferences.

Conclusions {#sec017}
===========

Two-thirds of HCV Ab positive individuals in MENA are chronically infected with HCV infection, implying that over 30% of infected individuals spontaneously clear their infection. Though there was extensive variation in the study-specific HCV viremic rates, the pooled mean viremic rates were similar regardless of risk population or subpopulation, country or subregion, HCV Ab prevalence in the background population, or sex. These findings argue for the use of one standardized HCV viremic rate, such as the overall pooled mean viremic rate provided in this study, in estimations of the number of HCV chronic carriers in different populations and countries. These findings also highlight the utility of using the pooled mean viremic rate as an indicator to track the progress in (and coverage of) HCV treatment programs in different risk populations and countries, as viral hepatitis treatment programs are established and/or expanded with the ultimate target of HCV elimination by 2030.
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